Dublin, March 25, 2019 (GLOBE NEWSWIRE) -- The "Global Non-Small Cell Lung Cancer Drugs Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.

The non-small cell lung cancer drugs market will register a CAGR of over 13% by 2023.

The increasing prevalence and incidence of non-small cell lung cancer are one of the primary factors driving the global non-small cell lung cancer drugs market growth.

The growing risk factors such as cigarette smoking, air pollution, secondary smoking, and occupational exposure is increasing the incidence of non-small cell lung cancer across the world. This will lead to an increase in the demand for non-small cell lung cancer drugs.

Strong drug pipeline and recent drug approvals

One of the growth drivers of the global non-small cell lung cancer drugs market is the strong drug pipeline and recent drug approvals. The development of new drugs and their approvals are helpful for the treatment of non-small lung cancer, which is expected to drive the market during the forecast period.

The high cost of treatment

One of the challenges in the growth of global non-small cell lung cancer drugs market is the high cost of treatment. Non-small cell lung cancer can be treated by surgery, chemotherapy, radiation therapy, targeted therapies, and immunotherapy which is very costly. Therefore, the high cost of treatment for non-small cell lung cancer will hamper the growth of the market during the forecast period.

Competitive Landscape

The market appears to be moderately fragmented and with the presence of several vendors. The vendors in the market are using predictive biomarkers for the development of cost-effective therapies with improved clinical benefits.

This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

Key Players

• Nlyte
• Panduit Corp.
• Schneider Electric
• Sunbird Inc.
• Vertiv Co.

Topics Covered

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

• Market ecosystem
• Market characteristics
• Market segmentation analysis

PART 04: MARKET SIZING

• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

PART 06: MARKET SEGMENTATION BY APPLICATION

• Comparison by application
• Asset and capacity management - Market size and forecast 2018-2023
• Energy management - Market size and forecast 2018-2023
• Power and cooling management - Market size and forecast 2018-2023
• Network management - Market size and forecast 2018-2023
• Market opportunity by application

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

• Geographic comparison
• North America - Market size and forecast 2018-2023
• APAC - Market size and forecast 2018-2023
• Europe - Market size and forecast 2018-2023
• Middle East and Africa - Market size and forecast 2018-2023
• South America - Market size and forecast 2018-2023
• Key leading countries
• Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

PART 11: MARKET TRENDS

• Increased use of analytics
• Emergence of hybrid IT infrastructure
• High adoption of IoT, in-built sensors and edge computing

PART 12: VENDOR LANDSCAPE

• Overview
• Landscape disruption

PART 13: VENDOR ANALYSIS

• Vendors covered
• Vendor classification
• Market positioning of vendors
• Nlyte
• Panduit Corp.
• Schneider Electric
• Sunbird Inc.
• Vertiv Co.

For more information about this report visit https://www.researchandmarkets.com/research/nrkdrx/nonsmall_cell?w=12

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
Related Topics: Lung Cancer Drugs 

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.